In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Hybaid

Division of Thermo Fisher Scientific Inc.

Latest From Thermo Hybaid

Can Ron Zwanziger Do It Again?

In the past two years, Inverness Medical Innovations has paid a total of roughly $500 million to buy five rapid point-of-care (POCT) diagnostic testing businesses, which now lie at the heart of its effort to expand in the POCT realm. These have laid the ground work for four subsequent transactions and related financings, all aimed at making Inverness a world leader in women's health and pregnancy testing. But what's of interest isn't so much the women's health play per se as the company's management tream, which has twice before built up POCT companies, then sold them for significant premiums.
Platform Technologies

'Tis the Season for a Flu Test

With the introduction of two new drugs for fighting the flu, the diagnostic tests for influenza become all the more important. Several niche players are hoping that physicians will use the tests to determine which patients have the flu in order to determine how to treat them. But for drug companies eager for as many patients as possible to use their therapies, the tests are a mixed blessing. They might help drug companies score points with payers, eager to curb the costs of treating an unpleasant but not usually serious disease, but they also help to limit the use of the drug to only those people who have the flu.
BioPharmaceutical Medical Device

Bets in Rapid DX

Quidel Corp. wants to become a consolidator of rapid diagnostics companies and products. The timing is right: just as big companies focused on the central laboratory are consolidating, opportunities abound in the rapid testing market, which has too many small competitors lacking critical mass and adequate distribution.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Thermo Bioanalysis Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Barry S Howe, Pres. & CEO
    John N Hatsopoulos, VP, CFO
  • Contact Info
  • Thermo Hybaid
    Phone: (505) 471-3232
    504 Airport Rd.
    Santa Fe, NM 87504-2108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register